CoChat

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study

Open access
Bermejo-Pareja, Felix, Antequera, Desiree, Vargas, Teo, Molina, Jose A, Carro, Eva · 2010 · BMC Neurology
Cited by 192

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Simple, non-invasive tests for early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers for the early diagnosis of Alzheimer disease (AD) are available. The clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. A biochemical marker that would support the clinical diagnosis and distinguish AD from other causes of dementia would therefore be of great value as a screening test. A total of 126 samples were obtained from subjects with AD, and age-sex-matched controls. Additionally, 51 Parkinson's disease (PD) patients were used as an example of another neurodegenerative disorder. We analyzed saliva and plasma levels of β amyloid (Aβ) using a highly sensitive ELISA kit. Results: We found a small but statistically significant increase in saliva Aβ 42 levels in mild AD patients. In addition, there were not differences in saliva concentration of Aβ 42 between patients with PD and healthy controls. Saliva Aβ 40 expression was unchanged within all the studied sample. The association between saliva Aβ 42 levels and AD was independent of established risk factors, including age or Apo E, but was dependent on sex and functional capacity. Conclusions: We suggest that saliva Aβ 42 levels could be considered a potential peripheral marker of AD and help discrimination from other types of neurodegenerative disorders. We propose a new and promising biomarker for early AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2377-10-108

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 192

Metadata

Authors
Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A., & Carro, E.
Venue
BMC Neurology
Published
2010-11-03
Volume
10
Issue
1
Pages
108-108
ISSN
1471-2377 (ISSN-L)
OpenAlex
W1973659432
Cited by
192
References
9
FWCI
3.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. https://app.cochat.ai/papers/10.1186/1471-2377-10-108
The paper
Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A., & Carro, E. (2010). Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurology. https://doi.org/10.1186/1471-2377-10-108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.